Prescription Medicine for Men Over 50: A Complete Clinical Guide

Why Men Over 50 Need a Different Prescription Framework

Men in their fifth decade and beyond are not simply older versions of their younger selves. Testosterone, insulin sensitivity, vascular compliance, and lean muscle mass all shift on predictable timelines. A 50-year-old man who feels "fine" may still carry a 10-year ASCVD risk above 10%, a total testosterone below 300 ng/dL, and a resting blood pressure that qualifies for pharmacotherapy under current guidelines.

The Hormonal Shift

Testosterone falls roughly 1 to 2% per year after age 30. By the time a man reaches 50, cumulative decline commonly places him in the clinically low range. Data from the European Male Aging Study (N=3,369) found that symptomatic androgen deficiency, defined by a combination of sexual symptoms and a morning total testosterone below 11 nmol/L, affected 2.1% of men aged 40 to 79, with prevalence rising sharply after 60 1.

The Cardiometabolic Shift

Visceral fat accumulates as testosterone falls and growth-hormone pulsatility decreases. This drives insulin resistance, dyslipidemia, and hypertension. The Framingham Heart Study showed that 10-year coronary heart disease risk doubles between ages 45 and 55 in men 2. The ACC/AHA Pooled Cohort Equations estimate that a typical 55-year-old white male with average risk factors carries roughly a 7.5 to 10% 10-year ASCVD risk, the threshold at which most guidelines recommend pharmacotherapy 3.

What This Guide Covers

The sections below walk through six prescription domains: testosterone replacement therapy (TRT), GLP-1 receptor agonists for weight and metabolic health, statins for cardiovascular risk, antihypertensives, phosphodiesterase-5 inhibitors (PDE5i) for erectile dysfunction, and hair-loss pharmacotherapy. Each section states the evidence grade, the standard doses, and the monitoring requirements.

Testosterone Replacement Therapy (TRT)

TRT is the most discussed prescription for men over 50 and, when properly indicated, one of the most effective. The Endocrine Society defines hypogonadism as a total morning testosterone below 300 ng/dL on two separate measurements, combined with symptoms such as reduced libido, fatigue, or loss of muscle mass 4.

Who Qualifies

Diagnosis requires both biochemical and symptomatic criteria. A total testosterone of 280 ng/dL in a man with no symptoms does not meet indication. Conversely, a symptomatic man with a borderline 320 ng/dL may still benefit if free testosterone is low due to elevated sex-hormone-binding globulin, which rises with age and obesity.

The Endocrine Society 2018 Clinical Practice Guideline states: "We recommend TRT for men with classic androgen deficiency syndromes (e.g., Klinefelter syndrome, hypothalamic or pituitary disorders) and for men with age-related hypogonadism who have consistent symptoms and unequivocally low testosterone concentrations" 4.

Formulation Options and Doses

• Testosterone cypionate or enanthate: 100 to 200 mg intramuscular (IM) every 1 to 2 weeks. Cost-effective, widely available, produces predictable peaks and troughs.
• Testosterone undecanoate (Aveed): 750 mg IM at 0, 4, and then every 10 weeks. Steadier levels, fewer injections, but requires in-office administration under an FDA REMS program 5.
• Topical gels (AndroGel 1%, 1.62%): 20.25 to 81 mg applied daily. Convenient but carries transfer risk to partners and children.
• Subcutaneous pellets (Testopel): 150 to 450 mg implanted every 3 to 6 months. Consistent levels; minor surgical procedure required.

Monitoring on TRT

Check total testosterone (target 400 to 700 ng/dL mid-cycle), hematocrit (stop or reduce dose if above 54%), PSA, and a basic metabolic panel at 3 months, then every 6 months once stable. The TRAVERSE trial (N=5,204, mean age 63.3 years) provided long-awaited cardiovascular safety data: testosterone-treated men did not experience higher rates of major adverse cardiovascular events than placebo over a median 21.7 months, though nonfatal arrhythmia and pulmonary embolism rates were modestly higher in the testosterone arm 6.

GLP-1 Receptor Agonists for Weight and Metabolic Health

GLP-1 agonists have reshaped obesity medicine. Men over 50 with a BMI >30 kg/m², or BMI >27 with at least one weight-related comorbidity, qualify under current FDA labeling.

Evidence Base

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo (P<0.001) 7. The SELECT trial (N=17,604), which enrolled adults with BMI >27 and established cardiovascular disease but without diabetes, showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a mean 34.2 months 8. For men over 50 with prior MI or stroke, that cardiovascular benefit is clinically significant independent of weight loss alone.

Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist, produced up to 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose 9. Tirzepatide also significantly improves testosterone levels in obese hypogonadal men, with one sub-analysis showing mean total testosterone rise from 230 to 370 ng/dL after 36 weeks, likely mediated through visceral fat reduction rather than direct gonadal action.

Dosing and Titration

Semaglutide (Wegovy) starts at 0.25 mg weekly for 4 weeks, escalating in 4-week steps to the 2.4 mg maintenance dose. Nausea affects roughly 44% of patients during titration but typically resolves within the first 8 to 12 weeks. Tirzepatide starts at 2.5 mg weekly, with monthly up-titration to a target of 10 to 15 mg.

Who Should Not Use GLP-1 Agonists

Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is an absolute contraindication. Pancreatitis history warrants caution. Active gallbladder disease is a relative contraindication, as GLP-1 agonists slow gallbladder emptying 10.

Statins for Cardiovascular Risk Reduction

Cardiovascular disease is the leading cause of death in American men, and statin therapy remains the most evidence-dense pharmacological intervention for primary and secondary prevention.

Guideline Recommendations

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "In adults aged 40 to 75 years with LDL-C 70 to 189 mg/dL and estimated 10-year ASCVD risk of 7.5% to <20%, initiate a moderate-intensity statin if a risk discussion favors treatment" 11. For risk above 20%, or in men with established ASCVD, high-intensity statin therapy is recommended.

Statin Intensity Classes

| Statin | Dose for High Intensity | Expected LDL-C Reduction | |---|---|---| | Rosuvastatin | 20 to 40 mg daily | ~50 to 55% | | Atorvastatin | 40 to 80 mg daily | ~46 to 51% | | Simvastatin | 40 mg daily | Moderate intensity only |

Monitoring and Side Effects

Myopathy occurs in roughly 5 to 10% of patients in real-world practice, though the SAMSON trial (N=60) demonstrated that 90% of statin-attributed muscle symptoms were not pharmacologically caused, as symptoms appeared equally on placebo and active drug 12. Check a baseline CK and liver enzymes, then recheck at 6 to 12 weeks. Men over 50 on high-intensity statins should also monitor for new-onset diabetes, as statins modestly raise fasting glucose.

Antihypertensives

Nearly 70% of American men over 60 have hypertension, defined as blood pressure at or above 130/80 mmHg under the 2017 ACC/AHA guidelines 13. Uncontrolled hypertension at 50 roughly doubles the lifetime risk of heart failure and stroke.

First-Line Drug Classes

The 2017 ACC/AHA Hypertension Guideline endorses four first-line classes: thiazide diuretics, ACE inhibitors, angiotensin-receptor blockers (ARBs), and calcium channel blockers (CCBs). Beta-blockers are reserved for men with concurrent coronary artery disease, heart failure with reduced ejection fraction, or arrhythmia.

Choosing by Comorbidity Profile

• Diabetes or CKD: ACE inhibitor (e.g., lisinopril 10 to 40 mg daily) or ARB (e.g., losartan 50 to 100 mg daily) for renoprotection 14.
• Isolated systolic hypertension (common after 55): Long-acting CCB, amlodipine 5 to 10 mg daily, is particularly effective because arterial stiffness responds well to dihydropyridine CCBs.
• Benign prostatic hyperplasia (BPH) co-existing: Alpha-blockers (tamsulosin 0.4 mg, doxazosin 1 to 8 mg) address both conditions simultaneously.

Blood Pressure Targets

The SPRINT trial (N=9,361) showed that targeting systolic BP below 120 mmHg reduced the composite cardiovascular outcome by 25% and all-cause mortality by 27% compared to a target below 140 mmHg 15. SPRINT excluded diabetic patients; for men with type 2 diabetes, the ADA recommends a target of <130/80 mmHg 16.

Erectile Dysfunction: PDE5 Inhibitors and Beyond

Erectile dysfunction affects an estimated 52% of men aged 40 to 70, per the Massachusetts Male Aging Study (N=1,290) 17. By age 60, moderate-to-complete ED affects close to 40% of men. ED is not just a quality-of-life concern. A 2018 meta-analysis in JAMA Network Open found that incident ED independently predicted cardiovascular events with a hazard ratio of 1.43 (95% CI 1.27 to 1.61) 18. Treat it, and investigate the underlying vascular risk.

PDE5 Inhibitor Options

Sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) all inhibit PDE5, increasing cyclic GMP and smooth-muscle relaxation in the corpus cavernosum.

• Sildenafil: 25 to 100 mg taken 30 to 60 minutes before sexual activity. Food reduces absorption; avoid high-fat meals. Works in ~70% of men with organic ED 19.
• Tadalafil: 10 to 20 mg as needed, or 2.5 to 5 mg daily for continuous coverage. The daily-dosing approach also reduces lower urinary tract symptoms in men with BPH, per FDA labeling 20.
• Avanafil: 50 to 200 mg, onset in as little as 15 minutes, fewer visual side effects due to PDE6 selectivity.

When PDE5i Fails

Second-line options include intraurethral alprostadil (MUSE, 125 to 1000 mcg), intracavernosal injection therapy (alprostadil 5 to 40 mcg), and vacuum erection devices. A penile prosthesis is a third-line surgical option with patient satisfaction rates above 90% in properly selected candidates 21.

Absolute Contraindication

PDE5 inhibitors are absolutely contraindicated with any nitrate (nitroglycerin, isosorbide mononitrate/dinitrate) because the combination can produce severe, potentially fatal hypotension. Screen every patient for nitrate use before prescribing.

Hair Loss: Finasteride and Dutasteride

Androgenetic alopecia affects roughly 50% of men by age 50. Beyond cosmetic impact, hair loss signals androgen-dependent scalp follicle miniaturization driven by dihydrotestosterone (DHT).

5-Alpha Reductase Inhibitors

Finasteride 1 mg daily (Propecia) inhibits type-2 5-alpha reductase, reducing scalp DHT by approximately 60%. In a 5-year randomized trial (N=1,553), finasteride increased hair count by a mean of 277 hairs in a 1-inch circle versus a loss of 100 hairs with placebo 22. Dutasteride 0.5 mg daily inhibits both type-1 and type-2 isoforms, reducing DHT by roughly 90% and showing superior hair counts to finasteride in head-to-head trials 23.

Sexual side effects (reduced libido, ejaculatory dysfunction) occur in roughly 2 to 4% of patients with finasteride. The FDA added a post-marketing label update in 2012 noting that these effects may persist after discontinuation in some men 24.

BPH Overlap

Men over 50 with both BPH and hair loss may benefit from finasteride 5 mg (Proscar) or dutasteride 0.5 mg (Avodart), which treat both conditions simultaneously. The PLESS trial (N=3,040) showed finasteride 5 mg reduced the risk of acute urinary retention by 57% over 4 years 25.

Comprehensive Monitoring Framework for Men Over 50 on Multiple Prescriptions

Most men over 50 end up on more than one prescription. Drug-drug interactions, compounding organ load, and overlapping side-effect profiles require a structured monitoring schedule.

Baseline Labs Before Starting Any Therapy

Order the following before initiating treatment in any of the above categories:

• Total and free testosterone, LH, FSH (if TRT is being considered)
• Fasting lipid panel, fasting glucose, HbA1c
• BMP (renal function, electrolytes)
• CBC with differential
• PSA (men 50 and above, or 40 and above with risk factors)
• Blood pressure measurement, BMI, waist circumference

Ongoing Monitoring Schedule

| Drug Class | Parameter | Frequency | |---|---|---| | TRT | Testosterone, hematocrit, PSA, CBC | 3 months, then every 6 months | | GLP-1 agonist | Weight, HbA1c, renal function, HR | Every 3 months | | Statin | LDL-C, CK (if symptomatic), LFTs | 6 to 12 weeks post-start, then annually | | ACE inhibitor / ARB | Potassium, creatinine | 2 to 4 weeks post-start, then every 6 months | | PDE5 inhibitor | Blood pressure, nitrate use review | Each visit | | Finasteride / Dutasteride | PSA (expect 50% reduction as new baseline) | Annually |

Drug Interaction Highlights

ACE inhibitors combined with potassium-sparing diuretics raise hyperkalemia risk. Statins combined with certain CYP3A4 inhibitors (e.g., fluconazole, clarithromycin) increase myopathy risk. TRT combined with anticoagulants may require INR adjustment. Always perform a full medication reconciliation at each follow-up visit.

Comparison Table: Key Prescription Options for Men Over 50

| Category | Drug Example | Starting Dose | Primary Outcome | Key Safety Watch | |---|---|---|---|---| | TRT | Testosterone cypionate | 100 mg IM q2w | Testosterone to 400 to 700 ng/dL | Hematocrit, PSA | | GLP-1 agonist | Semaglutide | 0.25 mg SC weekly | 15 to 22% weight loss | Nausea, pancreatitis hx | | Statin (high-intensity) | Rosuvastatin | 20 mg daily | LDL-C reduction ~50% | Myopathy, glucose | | Antihypertensive | Amlodipine | 5 mg daily | Systolic BP <130 mmHg | Peripheral edema | | PDE5 inhibitor | Tadalafil | 10 mg as needed | ED response ~70% | Nitrate use absolute CI | | 5-ARI | Finasteride | 1 to 5 mg daily | DHT reduction ~60% | Sexual side effects |

When to Refer to a Specialist

Primary care can manage most prescriptions in this guide, but certain situations warrant specialist involvement.

• Endocrinology: Total testosterone persistently below 150 ng/dL despite adequate TRT dosing, or suspicion of secondary hypogonadism (low LH/FSH with low testosterone), warrants pituitary MRI and endocrinology referral 4.
• Cardiology: Men with 10-year ASCVD above 20%, established coronary artery disease, or complex arrhythmia should have cardiology sign-off before starting TRT or PDE5i.
• Urology: PSA rise above 1.4 ng/mL per year on TRT, or baseline PSA above 4.0 ng/mL, triggers urology referral per the Endocrine Society guideline 4.
• Nephrology: eGFR below 30 mL/min/1.73m² changes dosing for metformin, ACE inhibitors, and several statins substantially.